Increased Signal Intensity in the Pulvinar on T1-Weighted Images: A Pathognomonic MR Imaging Sign of Fabry Disease

References

1. ↵
   Anderson W. A case of angiokeratoma. Br J Dermat 1898;10:113

   CrossRef
2. ↵
   Fabry J. Beitrag zur kenntnis de purpura hemorrhagica nodularis. Arch Dermatol Syph 1898;43:187

   CrossRef
3. ↵
   Brady R, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N Engl J Med 1967;276:1163–1167
4. ↵
   Desnick R, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th ed.. New York: McGraw-Hill,2001 :3733–3774
5. ↵
   Jinkins J, da Costa Leite C. Neurodiagnostic Imaging: Pattern Analysis and Differential Diagnosis. Philadelphia: Lippincott-Raven,1998 :1130
6. ↵
   Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol 1996;40:8–17

   CrossRefPubMedWeb of Science
7. ↵
   Crutchfield K, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998;50:1746–1749

   Abstract/FREE Full Text
8. ↵
   Moore DF, Scott LJC, Gladwin MT, et al. Regional cerebral hyper-perfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001;104:1506–1512

   Abstract/FREE Full Text
9. ↵
   Mirowitz S, Westrich TJ, Hirsch JD. Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. Radiology 1991;181:117–120

   PubMedWeb of Science
10. ↵
    McLaughlin A, Ye FQ, Berman KE, Mattay VS, Frank JA, Weinberger DR. Use of diffusible and nondiffusible tracers in studies of brain perfusion. In: Moonen C, Bandettini PA, eds. Functional MRI. Berlin: Springer-Verlag,2000 :37–46
11. ↵
    Henkelman R, Watts JF, Kucharczyk W. High signal intensity in MR images of calcified brain tissue. Radiology 1991;179:199–206

    PubMedWeb of Science
12. ↵
    Boyko O, Burger PC, Shelburne JD, Ingram P. Non-heme mechanisms for T1 shortening: pathologic, CT, and MR elucidation. AJNR Am J Neuroradiol 1992;13:1439–1445

    Abstract/FREE Full Text
13. ↵
    Gomori J, Grossman RI, Goldberg HI, Zimmerman RA, Bilaniuk LT. Intracranial hematomas: imaging by high-field MR. Radiology 1985;157:87–93

    PubMedWeb of Science
14. ↵
    Atlas S, Braffman BH, LoBrutto R, Elder DE, Herlyn D. Human malignant melanomas with varying degrees of melanin content in nude mice: MR imaging, histopathology, and electron paramagnetic resonance. J Comput Assist Tomogr 1990;14:547–554

    PubMed
15. ↵
    Fullerton G, Finnie MF, Hunter KE, Ord VA, Cameron IL. The influence of macromolecular polymerization of spin-lattice relaxation of aqueous solutions. Magn Reson Imaging 1987;5:353–370

    CrossRefPubMed
16. ↵
    Chawla S, Gupta RK, Kumar R, et al. Demonstration of scolex in calcified cysticercus lesion using gradient echo with or without corrected phase imaging and its clinical implications. Clin Radiol 2002;57:826–834

    PubMed
17. ↵
    Altarescu G, Moore DF, Pursley R, et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001;32:1559–1562

    Abstract/FREE Full Text
18. ↵
    Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. Biomed Central Neurol 2002;2 :4
19. ↵
    Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500

    CrossRefPubMedWeb of Science